Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MICA/MICB drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MICA / MICB ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Supports polymorphic variant screening (including MICA*008). |
View MICA Products |
| Gene Delivery | MICA / MICB Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional shedding assays. |
View MICA Products |
| Benchmark Ab | Anti-MICA/MICB Recombinant Monoclonal Antibody Recombinant positive control matching clinical-stage shedding-inhibitor sequences. |
View MICA Products |
| Validator | MICA / MICB siRNA Set For target knockdown verification in tumor cell lines. |
View MICA Products |
| Related Target A | NKG2D The primary activating receptor on NK cells and CD8+ T cells that interacts with MICA/MICB. |
View NKG2D Products |
| Related Target B | ADAM10 Metalloproteinase responsible for the proteolytic shedding of MICA/MICB from tumor surfaces. |
View ADAM10 Products |
| Related Target C | ADAM17 Synergistic shedding mediator; key target for preventing soluble decoy escape mechanisms. |
View ADAM17 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Polymorphism Coverage (MICA*008 vs. others) | Allele-specific recombinant proteins (HEK293 expressed, native glycosylation) |
| Shedding Inhibition Screening | High-titer Lentiviral vectors for stable MICA/MICB expression in target cell lines |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live MICA/MICB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MICA/MICB therapeutics is intensifying, with major players shifting focus from traditional mAbs to shedding-preventing antibodies and NK cell engagers (NKCEs). As first-generation therapies reach the clinic, the next wave of R&D is targeting the prevention of proteolytic shedding mediated by ADAM10/17, which generates soluble decoys (sMICA/sMICB) that suppress NK cell function. Overcoming this immune evasion mechanism represents the frontier of NKG2D-pathway oncology treatments.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Shedding-Inhibiting mAb | Dana-Farber / Harvard Spinoffs | Solid Tumors (CRC, Prostate) | Shedding Inhibition Assay (Need Lentivirus for Stable Cell Lines & sMICA detection) |
| NK Cell Engager (NKCE) | Innate Pharma, Sanofi | Hematological & Solid Tumors | Dual-binding Affinity (Need high-purity MICA, MICB, and NKG2D proteins) |
| CAR-NK / CAR-T | Academic Institutes, Biotech | Refractory Solid Tumors | Target Expression Verification (Need sequence-verified Lentivirus & flow-validated Abs) |